A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation
Autor: | Sara L. Deschaine, Lisa A. Farinelli, Mary R. Lee, Mehdi Farokhnia, Armin Sadighi, Lorenzo Leggio, Fatemeh Akhlaghi |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Agonist Baclofen medicine.drug_class media_common.quotation_subject Craving Alcohol Alcohol use disorder Pharmacology Placebo Article law.invention 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law medicine Humans Molecular Biology media_common business.industry musculoskeletal neural and ocular physiology Addiction medicine.disease 3. Good health Alcoholism Psychiatry and Mental health 030104 developmental biology Receptors GABA-B nervous system chemistry GABA-B Receptor Agonists medicine.symptom Laboratories business 030217 neurology & neurosurgery |
Zdroj: | Molecular psychiatry |
ISSN: | 1476-5578 1359-4184 |
DOI: | 10.1038/s41380-018-0287-y |
Popis: | Previous studies suggest that GABA-B receptor agonism may represent an effective pharmacological approach to treat addictive disorders. Baclofen is a selective GABA-B receptor agonist which has been investigated as a potential treatment for alcohol use disorder. However, research is needed to understand the biobehavioral mechanisms underlying baclofen’s effect on alcohol use. In the present randomized, double-blind, placebo-controlled study, thirty-four alcohol-dependent individuals were randomized to receive baclofen (30 mg/d) or placebo for a week, and then participated in a laboratory experiment consisting of three procedures: alcohol cue-reactivity, priming, and self-administration. During the experiment, craving and other subjective responses to alcohol were assessed, and blood samples were collected for pharmacokinetic measurements. The effects of baclofen on the relationships between different alcohol-related laboratory parameters were investigated. Baclofen pharmacokinetic parameters and their correlations with behavioral measures were also examined. Results showed that baclofen disrupted the link between alcohol priming and self-administration, as indicated by significant interaction effects between drug condition (baclofen vs. placebo) and some of the priming variables (alcohol craving: F3,9 = 6.03, p = 0.01; alcohol sedation: F3,6 = 7.16, p = 0.01) on the total amount of alcohol self-administered. Considerable interindividual variability in baclofen pharmacokinetic parameters was observed. Maximum plasma concentrations of baclofen negatively correlated with cue-induced alcohol craving (r = −0.57, p = 0.03) and priming-induced ratings of ‘like more’ (r = −0.59, p = 0.02). In conclusion, baclofen may work by dissociating the link between an initial drink (priming) and subsequent alcohol consumption (self-administration). Considerable pharmacokinetic variability is an important factor to take into account when employing baclofen as a treatment for alcohol use disorder. |
Databáze: | OpenAIRE |
Externí odkaz: |